Fresh Air, Sunshine, and Skiing with ISPE Boston!

Posted by ISPE Boston
On March 9, 2022

Last Friday, March 4 the ISPE Boston Chapter embarked on their Annual Ski Trip at Waterville Valley Ski Report in New Hampshire! With two full buses and additional carpooling up to the mountain; this turned out to be a very successful, completely sold out social event! With the restrictions starting to come down on mask-wearing […]

Welcome New Members February 2022!

Posted by ISPE Boston
On March 4, 2022

We would like to introduce the Members who joined ISPE in February 2022, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Chapter Member Anniversaries: March 2022

Posted by ISPE Boston
On March 4, 2022

Please congratulate the following members celebrating milestone anniversaries in March 2022. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Saboo Aghababayan, National Resilience Douglas Brenner, Pharmaceutical Automation LLC Richard Caires, Takeda Ronald Case, RCC Associates Charles Cooney, MIT Chemical Engineering Robert Davis, Process Control Solutions Michael Diker, […]

Intellia to Build Waltham Manufacturing Facility for its CRISPR-based Therapies

Posted by ISPE Boston
On March 3, 2022

Cambridge-based Intellia Therapeutics, a genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, plans to develop a 140,000-square-foot manufacturing facility in Waltham to support the manufacturing of key components for its CRISPR-based investigational therapies. “This new facility is a strategic investment, which in combination with existing capabilities and partnerships, will provide us with significant […]

Moderna Reports $12 Billion Profit

Posted by ISPE Boston
On March 3, 2022

mRNA pioneer Moderna has reported total revenue of $18.5 billion for the full year 2021, compared to $803 million in 2020. Product sales were $17.7 billion from sales of 807 million doses of the company’s Spikevax COVID-19 vaccine. Net income for 2021 was $12.2 billion, compared to a net loss of $747 million in 2020. […]

Eli Lilly to Create Genetic Medicine Research Hub in Boston Seaport District

Posted by ISPE Boston
On February 24, 2022

Eli Lilly has announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. This investment – part of the company’s strategy to advance RNA based therapeutics – builds on the 2020 acquisition and rapid expansion of Prevail Therapeutics, a […]

Agios Drug Wins FDA Approval

Posted by ISPE Boston
On February 24, 2022

Cambridge-based Agios Pharmaceuticals has announced that the FDA has approved Pyrukynd in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, debilitating, chronic hemolytic anemia. Pyrukynd is a first-in-class, oral PK activator and the first approved disease-modifying therapy for this disease. The drug was reviewed by the FDA under Priority Review and […]

Arrakis to Partner with Amgen on RNA-Targeted Small Molecule Therapeutics

Posted by ISPE Boston
On February 16, 2022

Waltham-based Arrakis Therapeutics has announced a research collaboration with drug giant Amgen. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders […]

Genzyme Name to Disappear as Sanofi Re-Brands

Posted by ISPE Boston
On February 8, 2022

Sanofi has unveiled a new corporate brand and logo that supports the modernization and transformation the company launched in December 2019. Current business units Sanofi Pasteur and Sanofi Genzyme, focused on vaccines and specialty care respectively, and all other acquired brands, will be united under the singular Sanofi name and brand. According to the company, […]

Vericel to Expand Manufacturing, Move Headquarters to Burlington

Posted by ISPE Boston
On February 8, 2022

Cambridge-based Vericel, a leader in advanced therapies for the sports medicine and severe burn care markets, has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington. The new facility, which will include approximately 125,000 square feet […]

Page 38 of 118«‹36 373839 40 ›»